Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-03-18
2008-03-18
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
11483659
ABSTRACT:
Compositions comprising inorganic phosphate and the nucleotides adenosine diphosphate and adenosine monophosphate; and their use for neutralizing effects of excess incident energy on the human body, particularly effects of ionizing radiation from nuclear or radiological energy sources, are disclosed and claimed.
REFERENCES:
patent: 6916795 (2005-07-01), Youssef
patent: 7112575 (2006-09-01), Youssef
patent: 2510407 (1983-02-01), None
patent: 2152814 (1985-08-01), None
patent: 47-026687 (1972-07-01), None
patent: 50-004094 (1975-01-01), None
Tikhomirova et al., “Comparative Radioprotective Effect of . . . ,” Radiobiologiya, 23(1), 100-104 (Sep.-Oct. 1983); Chemical Abstracts, 98, HCAPlus & CA Abstr. No. 157174 (1983); only HCAPlus Abstract supplied.
Grozdov, S. P., “Comparative Study of the Therapeutice Effect of Adenyl Compounds and their effect on Metabolism in Radiation Sickness,” Radiobiologiya, 20(4), 524-530 (1980); Chemical Abstracts, 93, Abstract No. 179729 (HCAPlus No. 579729) (1980).
Pantev et al., “Antiradiation Mixture and Ionic-bond of AET and Adenyl Nucleotides,” Strahlentherapie und Onkologie, 167(7), 422-426 (Jul. 1991); Medline No. 91313485; only Medline Abstract supplied.
Koshcheenko, N. N., “Biochemical Mechanism of the Radioprotective Action of Adenylic Compounds,” Nauchnye Doklady Vysshei Shkoly Biologicheskie, (Issue No. 2), pp. 5-18 (1992); Medline No. 82161127; only Medline title and citation supplied.
Ivnitsky et al., “Mechanisms of Cerebral Radiation Syndrome,” Radiatsionnaya Biologiya, Radioekologiya, 41(1), 48-55 (2001); Chemical Abstracts, 135, Abstr. No. 269359 (HCAPlus No. 271063) (2001; only HCAPlus Abstract supplied.
Nosov et al., “Metabolic Correction of Cerebral Radiation Syndrome,” Radiation Research, 152(5), 523-529 (1999); Chemical Abstracts, 132, Abstr. No. 20542 (HCAPlus No. 714176) (1999).
Pospilsil et al., “Radioprotection of Mouse Hemopoiesis by Dipyridamole and Adenosine Monophosphate in Fractionated Treatment,” Radiation Research, 142(1), 16-22 (1995); Chemical Abstracts, 122, Abstr. No. 259989 (HCAPlus No. 487342) (1999).
Grozdov et al., “Influence of ADP on the Course of Radiation Sickness and Some Metabolic Processes in Rats After Irradiation . . . ,” Radiobiologiya, 25(2), 234-238 (1985); Chemical Abstract, 103, Abstr. No. 2971 (HCAPlus No. 402971) (1985).
Savitskii et al., “Liver 5-Nucleotidase Activity of Rats with Radiation Sickness and Under Administration of ATP,” Radiobiologiya, 20(1), 103-106 (1980); Chemical Abstracts, 92, Abstr. No. 193556 (HCAPlus No. 193556) (1980).
Nikolov et al., “Therapeutic Effect of Adenosine Triphosphate Upon Survival Rate of Irradiated Rats,” Rentgenologiya i Radiologiya, 8(4), 209-214 (1969); Chemical Abstracts, 74, Abstr. No. 72504 (HCAPlus No. 72504) (1971).
Rogozkin et al., “Adenosine Triphosphoric Acids as Prophylactic and Therapeutic . . . ,” Suvremenna Meditsina, 21(6), 12-18 (1970); Chemical Abstracts, 74, Abstr. No. 10149 (HCAPlus No. 10149) (1971); only HCAPlus Abstract supplied.
Wagner et al., “Chemical Protection Against X-Radiation . . . ,” International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 12(2), 101-112 (1967); Chemical Abstracts, 67, Abstr. No. 70960 (HCAPlus No. 470960) (1967).
Sugahara et al., “Recovery from Radiation Injury with Nucleotide Mixtures in Mice,” Folia Biol. (Prague), 10(6), 461-464 (1964); Chemical Abstracts, 62, Abstr. No. 75954 (HCAPlus No. 75954) (1965).
Senagore et al., “Adenosine Triphosphate-Magnesium Chloride in Radiation Injury,” Surgery, 112(5), 933-939 (Nov. 1992); Medline No. 93068804.
Szeinfeld et al., “Response of Normal BALB/c Mouse Tissue to p(66 MeV)/Be Fast Neutron Radiation: Protection by Exogenous ATP,” Strahlentherapie und Onkologie, 168(3), 174-178 (Mar. 1992); Medline Accession No. 92205514.
Lehninger (I), Biochemistry, Second Edition, Worth Publisher, Inc., New York, NY, Jul. 1978, only pp. 315, 316 and 400 supplied.
Sigma Chemical Co., Biochemicals—Organic Compounds—Diagnostic Reagents (1995 Catalog), St. Louis, MO, 1995, only pp. 45-46 supplied.
J. F. Weiss , “Pharmacologic Approaches to Protection Against Radiation-induced Lethality and Other Damage,” Environmental Health Perspectives, 105(Suppl. 6), 1473-1478 (Dec. 1997).
Venes et al. (eds.), TaberÖs Cyclopedic Medical Dictionary, 19th Edition, F. A. Davis Co., Philadelphia, PA, 2001, only pp. 1817-1818 supplied.
Cantley, Jr., et al., “Vanadate Is a Potent (Na,K)-ATPase Inhibitor Found in ATP Derived From Muscle,” Journal of Biological Chemistry, 252(21), 7421-7423 (Nov. 10, 1977).
Beauge et al., “A Modifier of (Na+ + K+) ATPase in Commercial ATP,” Nature, 268, 355-356 (Jul. 28, 1977).
Josephson et al., “Isolation of a Potent (Na-K)ATPhase Inhibitor from Striated Muscles,” Biochemistry, 16(21), 4572-4578 (Oct. 18, 1977).
Sigma Chemical Co., Sigma Catalog -Biochemicals and Reagents for Life Science Research, 1997, St. Louis, MO, only pp. 65-66 supplied.
Lehninger (II)), Biochemistry, Second Edition, Worth Publishers, Inc., New York NY, Jul. 1978, only pp. 315-316 supplied.
Grant et al., “Modification of Survival of Gamma Irradiated Mice by Adenosine Nucleotides,” Strahlentherapie, 152(3), 285-291 (Sep. 1976).
Langendorff et al., “Adenosin-Nukleotide und Strahlenempfindlichkeit,” Strahlentherapie, 144(4), 451-456 (Oct. 1972).
Venes et al. (eds.) (II) , Taber's Cyclopedic Medical Dictionary, 19th Edition, F. A. Davis Co., Philadelphia, PA, 2001, only p. 2119 supplied, see definition of “synthase.”
Lehninger (III), Biochemistry, Second Edition, Worth Publishers, Inc., New York NY, Jul. 1978, only pp. 514-517 supplied.
Crane L. E.
Hoffman Wasson & Gitler
LandOfFree
Energy-protective composition comprising adenosine phosphates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Energy-protective composition comprising adenosine phosphates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Energy-protective composition comprising adenosine phosphates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3917517